Suppl Figure 1



Suppl Figure 2



Suppl Figure 3



Supplemental Figure 1. Phenotypical characterization of AZGP1 deleted mice. (A) Body weight of $AZGP^{+/-}$ and $AZGP1^{-/-}$ mice aged 4, 8 and 12 months. (B-D) Urea, creatinine and serum triglyceride levels of $AZGP1^{+/-}$ and $AZGP1^{-/-}$ mice at 12 months. Representative western blots for AZGP1 in serum (E) and renal homogenate (F) from $AZGP1^{+/+}$, $AZGP1^{+/-}$ and $AZGP1^{-/-}$ mice. Expression of renal E-cadherin and vimentin as shown by representative western blot (G) and quantitative RT-PCR (H,I) from 12 month old $AZGP^{+/-}$ and $AZGP1^{-/-}$ mice. n=6 for each data point in A-D, H,I. Values are given as mean ± SEM.

Supplemental Figure 2. Similar phenotype of wild-type and $AZGP1^{+/-}$ kidneys after 2 weeks of UUO. (A) Quantitative RT-PCR for fibrosis genes and tubular damage markers in UUO kidneys. (B) Quantification of birefringent collagen fibers in Picrosirius red stained UUO kidney sections. (C) Quantification of LTL positive area in kidney outer medulla region of UUO and AAN. (D) Quantification of cells positive for CD45 or F4/80 immunofluorescence in UUO kidney sections. UUO evaluated for all data at 2 weeks. Values are given as mean ± SEM, n=8.

Supplemental Figure 3. (A) Quantitative RT-PCR for αSMA expression in NRK-49F cells at 24 hours of TGF-β stimulation (2 ng/ml) in the presence or absence of recombinant murine AZGP1 (25 ng/ml). (B, C) Co-immunoprecipitations showing the lack of interaction between AZGP1 and TGF-β and AZGP1 and the TGF-β receptor II. (D, E) Quantitative RT-PCR for αSMA and collagen I expression in NRK-49F cells after 24 hours of TGF-β stimulation (2 ng/ml) with or without the β-adrenergic blocker propranolol (10 μM). Values are given as mean ± SEM, n=4 independent experiments for A-C. ***** $p < 0.05$, ** $p < 0.005$.